LONDON, UK: Allergy Therapeutics announced the appointment of Cheryl MacDiarmid as a Non-Executive Director of the Company, with effect from 27 October 2021.

Upon appointment Cheryl will also become a member of the Audit Committee.

Cheryl MacDiarmid has more than 25 years’ experience in commercial roles within the global pharmaceuticals sector. She brings significant marketing, strategy and management expertise, having worked for GlaxoSmithKline (GSK) since 1993, where she has focussed mainly on the commercial aspects of the business, developing a deep knowledge of sales and marketing operations in North America.

Cheryl MacDiarmid has significant senior management experience within GSK, initially in Canada and then in the US where she led the Respiratory Business Unit and associated US operations. In 2019 Cheryl was appointed Senior Vice President and Head, Global Commercial Strategy for ViiV Healthcare, the joint venture between GSK, Pfizer and Shionogi which specialises in the development of therapies for HIV.

Peter Jensen, Chairman of Allergy Therapeutics, commented: “We are delighted to welcome Cheryl to the Board of Allergy Therapeutics. Cheryl brings highly relevant experience, with her knowledge of the healthcare sector, expertise in marketing and commercial strategy, and her understanding of the US market, especially in the light of our recent announcement that our pivotal G306 Phase III trial is on track to commence in H2 2022 in US and Europe. I have no doubt she will be an important contributor to the Board.”

Commenting on her appointment, Cheryl MacDiarmid said: “I am delighted to be joining the Board of Allergy Therapeutics at an exciting time for the Company. I look forward to helping the Board to further strengthen Allergy’s leadership in the allergy immunotherapeutics field, providing innovative products to help people worldwide.”

Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries.

Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). www.allergytherapeutics.com